Nephrogenic systemic fibrosis, kidney disease, and gadolinium: Is there a link?

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 2, 2007, Pages 200-202

  Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

CHEMICALLY INDUCED DISORDER; FIBROSIS; HUMAN; KIDNEY FAILURE; NOTE;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY FAILURE;

EID: 34347340885     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00030107     Document Type: Editorial

References (17)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, Leboit PE: Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet 356: 1000-1001, 2000
2. Cowper SE: Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2006. Available at: http://www.icnfdr.org. Accessed December 26, 2006
3. Galan A, Cowper SE, Bucala R: Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18: 614-617, 2006
4. Cowper SE, Bucala R: Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear. Am J Dermatopathol 25: 358, 2003
5. Cowper SE: Nephrogenic fibrosing dermopathy: The first six years. Curr Opinion Rheum 15: 785-790, 2003
6. Dhaun N, Goddard J, Webb DJ: The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17: 943-955, 2006
7. Deo A, Fogel M, Cowper SE: Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2: 264 -267, 2007
8. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R: Nephrogenic systemic fibrosis: A mysterious disease in patients with renal failure - Role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2: 258-263, 2007
9. Grobner T: Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-1108, 2006
10. Marckmann P, Skov L, Rossen, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362, 2006
11. High WA, Ayers RA, Chandler J, Zito G, Cowper SE: Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-26, 2007
12. Boyd AC, Zic JA, Abraham JL: Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27-30, 2007
13. Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, Bensel K, LaFrance ND: Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34: 443-448, 1999
14. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y: Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24: 445-451, 2006
15. Joffe P, Thomsen HS, Meusel M: Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acta Radiol 5: 491-502, 1998
16. Runge VM: Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12: 309-314, 2001
17. White GW, Gibby WA, Tweedle MF: Comparison of Gd (DTPA-BMA) versus Gd (HP-D03A) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41: 272-278, 2006